BAY 1163877
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for BAY 1163877, covering 2018-04-18 to 2018-04-18. Get the full timeline:
Most recent: Clinical Trial Update: Phase I Dose Escalation Study of BAY 1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors [Phase 1]